• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$1.75 $0.18 (11.49%)

REAL-TIME: Last trade at

MEDICINOVA, INC.

NASDAQ:MNOV

MediciNova seeks PhIII funding for acute asthma drug despite PhIIb disappointment

MediciNova, Inc. Asthma Drug Fails Trial; Shares Crash -1.21(44.00%) @ 1:04PM EDT

MediciNova study doesn't yield significant results

MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary Endpoint; to Move Forward with End of Phase Meeting

MedicNova trading halted, news released

MedicNova reports results of phase 2b clinical trial of MN-221

MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma Exacerbations

MediciNova - MNOV - 2012 is off to a great start

MediciNova Reports First Quarter 2012 Results

MedicNova reports Q1 EPS (24c), one estimate (28c)

MediciNova Reports First Quarter 2012 Results

5 Socks Under $10 Set to Soar

This Developmental Pharma Has Potential To Be A Long Term Multibagger

Bio-Pharma Catalyst Trades: Focus On MediciNova

MediciNova To Release Asthma And COPD Trial Results In Q2

MediciNova Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain

MedicNova receives notice of Australian patent allowance for MN-166

MediciNova Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain

Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical Trial Results Soon

MediciNova Appoints David O'Toole CPA to its Board of Directors

MediciNova Appoints David O'Toole CPA to its Board of Directors

MediciNova Reports Fourth Quarter and Full Year 2011 Results

MedicNova reports Q4 EPS (22c), consensus (24c)

MediciNova Reports Fourth Quarter and Full Year 2011 Results

Companies reporting After the Market Close on Wednesday, March 28

MediciNova Management to Host a Conference Call to Discuss 2011 Earnings Thursday, March 29th at 5:

MediciNova Management to Host a Conference Call to Discuss 2011 Earnings Thursday, March 29th at 5:00 P.M. (EDT)

MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients Suffering from Acute Exac

MedicNova completes enrollment in Phase 2 MN-221 trial

MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients Suffering from Acute Exacerbations of Asthma

MediciNova Receives Notice of a Japanese Patent Allowance for a Method of Treating Neuropathic Pain

MediciNova (MNOV) Gets Notice of Allowance in Japan for MN-166 Patent Application

MedicNova and Jasdaq Market of Osaka receive of allowance for patent

MediciNova Receives Notice of a Japanese Patent Allowance for a Method of Treating Neuropathic Pain

MediciNova to Present at American Academy of Emergency Medicine Annual Meeting

Mid-day Movers (THLD, OPTT, ZNGA, MNOV, MNKD)

MedicNova falls 14.6%

24/7 Wall St. Closing Bell (DELL, EW, AKS, STLD, BRCM, GMCR, EDMC, NDAQ, QCOM, BZH, BSX, BCO, DO, LEA, MRK, TTWO, VIAB, ZNGA, MNOV, RGDX, BIOS, URG)

Mid-day Movers (VRNG, MNOV, ZNGA, BCO, ANF)

MedicNova rises 33.3%

See More Articles...